6-溴-4-甲氧基异喹啉 | 1015069-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 6-溴-4-甲氧基异喹啉
• 英文名称: 6-bromo-4-methoxyisoquinoline
• CAS: 1015069-74-5
• 化学式: C₁₀H₈BrNO
• 分子量: 238.084
• InChiKey: HGKFEVSHGSIHNL-UHFFFAOYSA-N

物化性质

• 沸点：
  352.0±22.0 °C(Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-溴-4-甲氧基异喹啉 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 28.0h， 生成 5-(4-methoxyisoquinolin-6-yl)thiazol-2-amine
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2
• 作为产物：
  描述：

  对溴苄胺 在 aluminum (III) chloride 、 氯化亚砜 、 lithium hydroxide monohydrate 、 水 、 sodium ethanolate 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.0h， 生成 6-溴-4-甲氧基异喹啉
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• [EN] AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH<br/>[FR] HÉTÉROCYCLES SUBSTITUÉS PAR AMINO, COMPOSITIONS À BASE DE CEUX-CI ET PROCÉDÉS DE TRAITEMENT À L'AIDE DE CEUX-CI
  申请人：SIGNAL PHARM LLC

  公开号：WO2008036308A2

  公开（公告）日：2008-03-27

  [EN] Provided herein are Heterocyclic Compounds having the following structure: Formula (I) wherein R¹, R², X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.
  [FR] L'invention concerne des composés hétérocycliques présentant la structure suivante : Formule (I) dans laquelle R¹, R², X, Y et Z sont tels que définis présentement, des compositions comprenant une quantité efficace d'un composé hétérocyclique et des procédés pour traiter ou prévenir un cancer, des conditions inflammatoires, des conditions immunologiques, des conditions métaboliques et des conditions que l'on peut traiter ou prévenir par l'inhibition d'une voie de kinase comprenant l'administration d'une quantité efficace d'un composé hétérocyclique à un patient en ayant besoin.
• [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：[en]PROTHENA BIOSCIENCES LIMITED

  公开号：WO2023107714A2

  公开（公告）日：2023-06-15

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.